FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158532310> ?p ?o ?g. }

• W2158532310 endingPage "1860" @default.
• W2158532310 startingPage "1852" @default.
• W2158532310 abstract "PURPOSE We performed a pilot phase II study to evaluate the potential for delivery of rapidly sequenced high-dose chemotherapy treatments rescued with autologous peripheral-blood progenitor cells (PBP) in patients with previously untreated, advanced ovarian cancer. PATIENTS AND METHODS A single cycle of mobilization was used, primed with cyclophosphamide (CPA)/paclitaxel (Txl) and filgrastim (granulocyte colony-stimulating factor [G-CSF]), followed by three cycles of high-dose carboplatin (CBDCA)/Txl and one cycle of high-dose melphalan (MEL), each rescued by PBP. We then analyzed the outcome for a total of 56 consecutive patients treated with high-dose chemotherapy as part of this program. RESULTS In the phase II pilot, 21 patients were enrolled. There were no treatment-related deaths through 98 high-dose treatments, although 34 treatments were complicated by hospitalization, primarily for neutropenic fever. Seventy-six percent of patients experienced grade 3 to 4 gastrointestinal toxicity and 62% experienced grade 2 to 3 neuropathy. Five of 15 (33%) patients who underwent second-look surgery attained a pathologic complete response. In the overall analysis, 56 patients were reviewed. Forty-four patients were assessable for response by second-look surgery or clinical progression. Fifteen of 44 patients achieved a pathologic complete response (34%). The pathologic complete response rate in optimal-disease patients was 12 of 22 (55%), while only three of 22 (13%) suboptimal stage III and IV patients achieved a pathologic complete response. CONCLUSION The Gynecologic Oncology Group has initiated a pilot phase II trial of this approach in patients with optimally debulked stage III ovarian cancer. There is no evidence to support the use of this or other aggressive regimens outside of a clinical trial." @default.
• W2158532310 created "2016-06-24" @default.
• W2158532310 creator A5006624723 @default.
• W2158532310 creator A5007499006 @default.
• W2158532310 creator A5019416229 @default.
• W2158532310 creator A5023020931 @default.
• W2158532310 creator A5039225060 @default.
• W2158532310 creator A5039340291 @default.
• W2158532310 creator A5041667140 @default.
• W2158532310 creator A5047041628 @default.
• W2158532310 creator A5051707990 @default.
• W2158532310 creator A5054602117 @default.
• W2158532310 creator A5056382675 @default.
• W2158532310 creator A5057261493 @default.
• W2158532310 creator A5060116963 @default.
• W2158532310 creator A5071493961 @default.
• W2158532310 creator A5073323475 @default.
• W2158532310 creator A5086908552 @default.
• W2158532310 date "1998-05-01" @default.
• W2158532310 modified "2023-09-27" @default.
• W2158532310 title "Phase II study of dose-dense high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer." @default.
• W2158532310 cites W1914060921 @default.
• W2158532310 cites W2116996913 @default.
• W2158532310 doi "https://doi.org/10.1200/jco.1998.16.5.1852" @default.
• W2158532310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9586901" @default.
• W2158532310 hasPublicationYear "1998" @default.
• W2158532310 type Work @default.
• W2158532310 sameAs 2158532310 @default.
• W2158532310 citedByCount "42" @default.
• W2158532310 countsByYear W21585323102016 @default.
• W2158532310 crossrefType "journal-article" @default.
• W2158532310 hasAuthorship W2158532310A5006624723 @default.
• W2158532310 hasAuthorship W2158532310A5007499006 @default.
• W2158532310 hasAuthorship W2158532310A5019416229 @default.
• W2158532310 hasAuthorship W2158532310A5023020931 @default.
• W2158532310 hasAuthorship W2158532310A5039225060 @default.
• W2158532310 hasAuthorship W2158532310A5039340291 @default.
• W2158532310 hasAuthorship W2158532310A5041667140 @default.
• W2158532310 hasAuthorship W2158532310A5047041628 @default.
• W2158532310 hasAuthorship W2158532310A5051707990 @default.
• W2158532310 hasAuthorship W2158532310A5054602117 @default.
• W2158532310 hasAuthorship W2158532310A5056382675 @default.
• W2158532310 hasAuthorship W2158532310A5057261493 @default.
• W2158532310 hasAuthorship W2158532310A5060116963 @default.
• W2158532310 hasAuthorship W2158532310A5071493961 @default.
• W2158532310 hasAuthorship W2158532310A5073323475 @default.
• W2158532310 hasAuthorship W2158532310A5086908552 @default.
• W2158532310 hasConcept C121608353 @default.
• W2158532310 hasConcept C126322002 @default.
• W2158532310 hasConcept C141071460 @default.
• W2158532310 hasConcept C143998085 @default.
• W2158532310 hasConcept C2776694085 @default.
• W2158532310 hasConcept C2776755627 @default.
• W2158532310 hasConcept C2777767877 @default.
• W2158532310 hasConcept C2778239845 @default.
• W2158532310 hasConcept C2778684742 @default.
• W2158532310 hasConcept C2778822529 @default.
• W2158532310 hasConcept C2779171977 @default.
• W2158532310 hasConcept C2780427987 @default.
• W2158532310 hasConcept C2781451048 @default.
• W2158532310 hasConcept C31760486 @default.
• W2158532310 hasConcept C71924100 @default.
• W2158532310 hasConcept C90924648 @default.
• W2158532310 hasConceptScore W2158532310C121608353 @default.
• W2158532310 hasConceptScore W2158532310C126322002 @default.
• W2158532310 hasConceptScore W2158532310C141071460 @default.
• W2158532310 hasConceptScore W2158532310C143998085 @default.
• W2158532310 hasConceptScore W2158532310C2776694085 @default.
• W2158532310 hasConceptScore W2158532310C2776755627 @default.
• W2158532310 hasConceptScore W2158532310C2777767877 @default.
• W2158532310 hasConceptScore W2158532310C2778239845 @default.
• W2158532310 hasConceptScore W2158532310C2778684742 @default.
• W2158532310 hasConceptScore W2158532310C2778822529 @default.
• W2158532310 hasConceptScore W2158532310C2779171977 @default.
• W2158532310 hasConceptScore W2158532310C2780427987 @default.
• W2158532310 hasConceptScore W2158532310C2781451048 @default.
• W2158532310 hasConceptScore W2158532310C31760486 @default.
• W2158532310 hasConceptScore W2158532310C71924100 @default.
• W2158532310 hasConceptScore W2158532310C90924648 @default.
• W2158532310 hasIssue "5" @default.
• W2158532310 hasLocation W21585323101 @default.
• W2158532310 hasLocation W21585323102 @default.
• W2158532310 hasOpenAccess W2158532310 @default.
• W2158532310 hasPrimaryLocation W21585323101 @default.
• W2158532310 hasRelatedWork W1967715255 @default.
• W2158532310 hasRelatedWork W2060767396 @default.
• W2158532310 hasRelatedWork W2072767112 @default.
• W2158532310 hasRelatedWork W2105623825 @default.
• W2158532310 hasRelatedWork W2125755594 @default.
• W2158532310 hasRelatedWork W2158532310 @default.
• W2158532310 hasRelatedWork W2335066363 @default.
• W2158532310 hasRelatedWork W2410995755 @default.
• W2158532310 hasRelatedWork W2443311901 @default.
• W2158532310 hasRelatedWork W2968124559 @default.
• W2158532310 hasVolume "16" @default.
• W2158532310 isParatext "false" @default.
• W2158532310 isRetracted "false" @default.
• W2158532310 magId "2158532310" @default.

• next